Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Urinary bladder neoplasms | D001749 | — | C67 | — | — | 1 | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Lymphoma | D008223 | — | C85.9 | 1 | 2 | — | — | — | 3 |
Leukemia | D007938 | — | C95 | 2 | 1 | — | — | — | 2 |
Myeloid leukemia acute | D015470 | — | C92.0 | 2 | 1 | — | — | — | 2 |
Myeloid leukemia | D007951 | — | C92 | 2 | 1 | — | — | — | 2 |
Myelodysplastic syndromes | D009190 | — | D46 | 1 | 1 | — | — | — | 1 |
Myeloproliferative disorders | D009196 | — | D47.1 | 1 | 1 | — | — | — | 1 |
Biphenotypic leukemia acute | D015456 | — | C95.0 | 1 | 1 | — | — | — | 1 |
Preleukemia | D011289 | — | — | 1 | 1 | — | — | — | 1 |
Syndrome | D013577 | — | — | 1 | 1 | — | — | — | 1 |
T-cell lymphoma | D016399 | — | — | — | 1 | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Recurrence | D012008 | — | — | 1 | — | — | — | — | 1 |
Non-hodgkin lymphoma | D008228 | — | C85.9 | 1 | — | — | — | — | 1 |
Follicular lymphoma | D008224 | — | C82 | 1 | — | — | — | — | 1 |
Large b-cell lymphoma diffuse | D016403 | — | C83.3 | 1 | — | — | — | — | 1 |
B-cell lymphoma | D016393 | — | — | 1 | — | — | — | — | 1 |
Drug common name | Lenograstim |
INN | lenograstim |
Description | Lenograstim is a recombinant granulocyte colony-stimulating factor which functions as an immunostimulator. It is developed by Chugai Pharmaceuticals under the brand name Granocyte.
|
Classification | Protein |
Drug class | colony-stimulating factors: granulocyte colony-stimulating factors (G-CSF) |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | — |
PDB | — |
CAS-ID | — |
RxCUI | — |
ChEMBL ID | CHEMBL2109128 |
ChEBI ID | — |
PubChem CID | — |
DrugBank | — |
UNII ID | 6WS4C399GB (ChemIDplus, GSRS) |